1. Home
  2. CELC vs PKST Comparison

CELC vs PKST Comparison

Compare CELC & PKST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • PKST
  • Stock Information
  • Founded
  • CELC 2011
  • PKST 2008
  • Country
  • CELC United States
  • PKST United States
  • Employees
  • CELC N/A
  • PKST 38
  • Industry
  • CELC Medical Specialities
  • PKST Real Estate Investment Trusts
  • Sector
  • CELC Health Care
  • PKST Real Estate
  • Exchange
  • CELC Nasdaq
  • PKST Nasdaq
  • Market Cap
  • CELC 327.3M
  • PKST 419.1M
  • IPO Year
  • CELC 2017
  • PKST N/A
  • Fundamental
  • Price
  • CELC $10.53
  • PKST $11.22
  • Analyst Decision
  • CELC Strong Buy
  • PKST Buy
  • Analyst Count
  • CELC 6
  • PKST 2
  • Target Price
  • CELC $30.17
  • PKST $15.00
  • AVG Volume (30 Days)
  • CELC 195.9K
  • PKST 130.3K
  • Earning Date
  • CELC 05-14-2025
  • PKST 05-08-2025
  • Dividend Yield
  • CELC N/A
  • PKST 7.97%
  • EPS Growth
  • CELC N/A
  • PKST N/A
  • EPS
  • CELC N/A
  • PKST N/A
  • Revenue
  • CELC N/A
  • PKST $228,073,000.00
  • Revenue This Year
  • CELC N/A
  • PKST N/A
  • Revenue Next Year
  • CELC N/A
  • PKST N/A
  • P/E Ratio
  • CELC N/A
  • PKST N/A
  • Revenue Growth
  • CELC N/A
  • PKST 10.26
  • 52 Week Low
  • CELC $7.58
  • PKST $9.89
  • 52 Week High
  • CELC $19.77
  • PKST $16.26
  • Technical
  • Relative Strength Index (RSI)
  • CELC 51.41
  • PKST 38.37
  • Support Level
  • CELC $9.64
  • PKST $11.07
  • Resistance Level
  • CELC $11.66
  • PKST $11.68
  • Average True Range (ATR)
  • CELC 0.66
  • PKST 0.46
  • MACD
  • CELC -0.04
  • PKST -0.08
  • Stochastic Oscillator
  • CELC 44.06
  • PKST 5.01

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About PKST Peakstone Realty Trust

Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.

Share on Social Networks: